Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Neonatal Platelet Transfusion Threshold Trial
NCT06676904 · View on ClinicalTrials.gov ↗
Study Summary
The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0/7 to 26 6/7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0/7 weeks' postmenstrual age (PMA).
Conditions Studied
Interventions
- PROCEDURE Higher Platelet Transfusion Threshold
- PROCEDURE Lower Platelet Transfusion Threshold
Study Locations (20)
Ohio
- Cincinnati Children's Medical Center — Cincinnati
- Case Western Reserve University, Rainbow Babies and Children's Hospital — Cleveland
- Nationwide Children's Hospital — Columbus
Texas
- University of Texas Southwestern Medical Center at Dallas — Dallas
- University of Texas Health Science Center at Houston — Houston
- Pediatrix Medical Group — San Antonio
California
- Stanford University — Palo Alto
- Sharp Mary Birch Hospital for Women & Newborns — San Diego
Alabama
- University of Alabama at Birmingham — Birmingham
Colorado
- University of Colorado — Aurora
Georgia
- Emory University — Atlanta
Illinois
- Northwestern Lurie Children's Hospital of Chicago — Chicago
Iowa
- University of Iowa — Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,433 participants |
| Start Date | 2025-06-13 |
| Est. Completion | 2031-04-30 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06676904
The ClinicalTrials.gov registry entry for NCT06676904 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,433 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NICHD Neonatal Research Network, which has 44 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 7 conditions, with Thrombosis appearing as the primary indexed condition, and to 2 interventions — of which Higher Platelet Transfusion Threshold is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06676904 reports 20 study locations spanning 15 distinct geographic areas — top geographies include Ohio, Texas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06676904 about?
NCT06676904 is a clinical study titled "Neonatal Platelet Transfusion Threshold Trial". The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0/7 to 26 6/7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0/7 weeks' postmenstrual age (PMA).
What is the current status of trial NCT06676904?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,433 participants. The study started on 2025-06-13. Estimated completion is 2031-04-30.
What conditions does trial NCT06676904 study?
This clinical trial studies the following conditions: Thrombosis, Thrombocytopenia, Infant, Small for Gestational Age, Infant, Newborn, Diseases, Neonatal. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06676904?
The interventions under investigation include: Higher Platelet Transfusion Threshold (PROCEDURE), Lower Platelet Transfusion Threshold (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06676904?
This trial is sponsored by NICHD Neonatal Research Network, which has 44 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06676904 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.